Literature DB >> 16958035

Schizophrenia is not associated with the functional candidate gene ERBB3: results from a case-control study.

Tetsufumi Kanazawa1, Stephen J Glatt, Atsushi Tsutsumi, Hiroki Kikuyama, Jun Koh, Hiroshi Yoneda, Ming T Tsuang.   

Abstract

Increasing evidence has supported the hypothesis of a neurodevelopmental component in the etiology of schizophrenia. Recently, several independent microarray gene expression studies have revealed downregulated expression of myelin-related genes in the postmortem brains of schizophrenia patients. Complete myelination of the cortex has been observed to occur in late adolescence and early adulthood, which is typically the age of onset of schizophrenia. ERBB3 is a gene which has not only been found to be downregulated in schizophrenia simultaneously in three microarray studies, but also is a strong candidate because of its potential role in neurodevelopment as a receptor of NRG1. Therefore, we performed association analysis of seven nonsynonymous SNPs in this gene. Two SNPs in ERBB3 (rs773123 and rs2271188) were polymorphic in our samples, neither of which showed significant evidence of association with the illness (P = 0.639 and 0.561, respectively). Because replication across such studies is notoriously difficult, the microarray evidence implicating ERBB3 still strongly supports some role of this gene in schizophrenia. However, our failure to find genetic association suggests that the differential expression of ERBB3 in schizophrenia may be environmentally driven, or involve cis- or trans-acting genetic factors beyond the boundaries of the gene itself.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16958035     DOI: 10.1002/ajmg.b.30367

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  6 in total

1.  Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia.

Authors:  Shruti N Mitkus; Thomas M Hyde; Radhakrishna Vakkalanka; Bhaskar Kolachana; Daniel R Weinberger; Joel E Kleinman; Barbara K Lipska
Journal:  Schizophr Res       Date:  2007-10-26       Impact factor: 4.939

Review 2.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

3.  Association and interaction analyses of NRG1 and ERBB4 genes with schizophrenia in a Japanese population.

Authors:  Sae Shiota; Mamoru Tochigi; Hiroko Shimada; Jun Ohashi; Kiyoto Kasai; Nobumasa Kato; Katsushi Tokunaga; Tsukasa Sasaki
Journal:  J Hum Genet       Date:  2008-08-14       Impact factor: 3.172

4.  Schizophrenia is not associated with the ERBB3 gene in a Han Chinese population sample: Results from case-control and family-based studies.

Authors:  Dawei Li; Guang He; Yifeng Xu; Yun Duan; Niufan Gu; Xingwang Li; Yongyong Shi; Wei Qin; Guoyin Feng; Lin He
Journal:  Genet Mol Biol       Date:  2009-12-01       Impact factor: 1.771

5.  ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease.

Authors:  Yuriko Iwakura; Hiroyuki Nawa
Journal:  Front Cell Neurosci       Date:  2013-02-13       Impact factor: 5.505

6.  Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).

Authors:  Damien Coté; Alex Eustace; Sinead Toomey; Mattia Cremona; Malgorzata Milewska; Simon Furney; Aoife Carr; Joanna Fay; Elaine Kay; Susan Kennedy; John Crown; Bryan Hennessy; Stephen Madden
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.